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Abstract
DNA methylation is one of the best-characterized epigenetic modifications and has been
implicated in numerous biological processes, including transposable element silencing, genomic
imprinting and X chromosome inactivation. Compared with other epigenetic modifications, DNA
methylation is thought to be relatively stable. Despite its role in long-term silencing, DNA
methylation is more dynamic than originally thought as active DNA demethylation has been
observed during specific stages of development. In the past decade, many enzymes have been
proposed to carry out active DNA demethylation and growing evidence suggests that, depending
on the context, this process may be achieved by multiple mechanisms. Insight into how DNA
methylation is dynamically regulated will broaden our understanding of epigenetic regulation and
have great implications in somatic cell reprogramming and regenerative medicine.
Eukaryotic chromatin contains a wealth of information required for the growth and
development of a multicellular organism. This information is not only stored genetically in
the DNA sequence itself but also epigenetically through DNA methylation and post-
translational modifications of histone proteins1,2. Although every nucleotide in the genome
has the potential to be transcribed3, the presence or absence of specific epigenetic marks
influences gene expression, resulting in a transcriptional programme that specifies for a
particular cell type. For example, in embryonic stem (ES) cells, active gene expression
marks are found at pluripotent genes and repressive marks are found at lineage-specific
genes. Thus, different cell types can be defined by their epigenetic and gene expression
profiles.
During development, these transcriptional programmes undergo dynamic changes that
ultimately lead to the production of distinct cell types and tissues that make up an organism.
Accommodating such a transcriptional programme requires an epigenome that is both
dynamic and flexible. Furthermore, the diversity of genetic material to be regulated
necessitates the use of marks corresponding to short-term and long-term epigenetic memory,
depending on the transcriptional requirements of the cell (as well as those of future
generations). Developmental genes that are needed during the later stages of development
are transiently held in a repressed state during early development. This is achieved through
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short-term epigenetic marks such as histone modifications, which can be removed before or
within a few cell divisions.
By contrast, other regions of the genome are marked with epigenetic information that is
stably maintained and heritable after many cell divisions. For example, imprinted genes,
transposons and the inactive X chromosome require long-term silencing that is sustained
throughout the development and lifespan of an organism. This is generally achieved by
DNA methylation, an epigenetic mark that refers to the addition of a methyl group to the
fifth carbon of base C. Because DNA methylation provides heritable, long-term silencing
that is crucial for an organism, aberrant DNA methylation has been associated with cancer,
imprinting-related diseases and psychiatric disorders4-7.
In mammals, DNA methylation occurs predominantly in the context of CpG (C followed by
G) dinucleotides, whereas DNA methylation in plants can occur at C bases in diverse
sequence contexts8. The enzymes responsible for this modification, DNA methyltransferases
(DNMTs), are well characterized and conserved in mammals and plants8. DNMTs fall under
two categories: de novo and maintenance9. Patterns of DNA methylation are initially
established by the de novo DNA methyltransferases DNMT3A and DNMT3B during the
blastocyst stage of embryonic development10,11 (FIG. 1). These methyl marks are then
faithfully maintained during cell divisions through the action of the maintenance
methyltransferase, DNMT1, which has a preference for hemi-methylated DNA12-14. Both
the establishment and maintenance of DNA methylation patterns are crucial for development
as mice deficient in DNMT3B or DNMT1 are embryonic lethal11,15 and DNMT3A-null
mice die by 4 weeks of age11.
Although DNA methylation has been viewed as a stable epigenetic mark, studies in the past
decade have revealed that this modification is not as static as once thought. In fact, loss of
DNA methylation, or DNA demethylation, has been observed in specific contexts (see
below) and can occur through active or passive mechanisms (FIG. 1). Active DNA
demethylation is the enzymatic process that results in the removal of the methyl group from
5-methylcytosine (5meC) by breaking a carbon-carbon bond. By contrast, passive DNA
demethylation refers to the loss of the methyl group from 5meC when DNMT1 is inhibited
or absent during successive rounds of DNA replication. whereas passive DNA
demethylation is generally understood and accepted, the subject of active DNA
demethylation has been controversial16.
In this Review, we explore what is known about active DNA demethylation and the disputes
that are embedded in this field. First, we describe the contexts in which DNA demethylation
has been observed and discuss the evidence that supports an active mechanism. we then
present the many enzymes that have been proposed to carry out active DNA demethylation.
we conclude by discussing emerging themes and highlighting the remaining questions in this
exciting field.
Evidence for active DNA demethylation
Even though DNA methylation contributes to stable, long-term and heritable silencing, it
has become apparent that in some instances DNA methylation levels can rapidly change by
mechanisms involving active DNA demethylation. Genome-wide and gene-specific
demethylation events have both been observed, but current evidence suggests that the former
only occurs at specific times during early development, whereas the latter occurs in somatic
cells responding to specific signals.
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Genome-wide DNA demethylation of paternal pronuclei
Prior to fertilization, mammalian gametes are at different stages of the cell cycle and their
genomes are organized differently. The egg is meiotically arrested at metaphase II, resulting
in a diploid genome that is packaged with histones. Mature sperm, however, have completed
meiosis, but their haploid genomes are packaged with protamines instead of histones. when
a sperm penetrates the zona pellucida to fertilize the egg, both gametes undergo rapid
changes. The egg completes its second meiosis resulting in the extrusion of one copy of the
genome as the polar body; the sperm reorganizes its genomic DNA by replacing protamines
with histone proteins.
Shortly after the protamine-histone exchange, the sperm-derived paternal pronucleus
undergoes genome-wide DNA demethylation17,18, an event that occurs quite rapidly within
4-8 hours post-fertilization (FIG. 2a). Although there are some disputes regarding the timing
and synchrony of DNA replication in the zygote19-25, loss of DNA methylation is seen
before the completion of the first cell division. Thus, it is unlikely that a passive
demethylation mechanism is the cause for this observation. Furthermore, when zygotes were
treated with the replication inhibitor aphidicolin, paternal genome demethylation was still
detected17,26, further supporting an active demethylation mechanism.
Paternal genome demethylation has been observed in many mammalian organisms,
including human, mouse, rat, bovine and pig17,18,27,28, but seems to be absent from others,
such as sheep29. when sheep sperm are injected into mouse oocytes, demethylation is seen in
the sheep-derived paternal genome30, suggesting that the demethylating factor or factors are
contributed by the oocyte. However, sheep oocytes injected with mouse sperm also resulted
in demethylation of the mouse-derived paternal genome30. Although this occurs to a lesser
extent compared to mouse oocytes, it is likely that factors present in the sperm or features
unique to the paternal genome also contribute to demethylation. Consistent with this notion,
mouse oocytes can demethylate multiple male pronuclei31, but are incapable of
demethylating the additional maternal genome in parthenogenetic, gynogenetic and digynic
triploid zygotes32.
Although immunostaining studies suggest that demethylation occurs globally, bisulphite
sequencing indicates that some genomic regions are resistant to such a wave of
demethylation. These genomic regions include imprinting control regions33, intracisternal
A-particle (IAP) retrotransposons34 and centric and pericentric heterochromatin31,35. It is
not clear why these genomic regions are resistant to this wave of DNA demethylation, but
one possibility is that methylation of these regions may be required to ensure transcriptional
repression and chromosomal stability. Additionally, the maternal genome remains
methylated during this time even though it is exposed to the same cytoplasmic factors.
Insight into how some regions in the paternal genome are targeted for DNA demethylation
whereas other regions are resistant may also provide clues as to how the maternal genome is
protected from active demethylation (BOX 1).
The significance of zygotic paternal genome DNA demethylation is unclear at present.
Genome-wide demethylation may facilitate transcriptional activation of the paternal
genome36, which has been reported to occur before transcriptional activation of the maternal
genome in some species37. Although some transposable elements and repeat sequences have
been identified to be resistant to DNA demethylation, it is likely that others are still targets
of DNA demethylation, given that these types of sequences account for half of the genome.
whether demethylation of transposable elements and repeat sequences results in their
reactivation and, if so, what the significance of their reactivation is remains to be
determined.
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Genome-wide DNA demethylation of primordial germ cells
After fertilization, the one-cell zygote undergoes several cell divisions that ultimately lead to
formation of the blastocyst. During this developmental period, the maternal genome
undergoes passive DNA demethylation (FIG. 2a) — a gradual loss of DNA methylation
occurs with each cell division38 in a replication-dependent manner39. Consistent with this,
maternally contributed DNMT1 (also known as DNMT1o) is excluded from the nucleus40.
Although passive DNA demethylation seems to affect a large part of the genome, imprinted
genes still retain their methylation marks. Recent genetic studies indicate that maternal and
zygotic DNMT1 (ReF. 41) and the zinc finger protein ZFP57 (ReF. 42) are required to
maintain the DNA methylation imprints during pre-implantation development.
At embryonic day 7.5 (E7.5), signals originating from the extraembryonic ectoderm and the
visceral endoderm instruct a subset of posterior epiblast cells to become primordial germ
cells (PGCs). Specification of PGCs involves the BMP4 and BMP8 signalling pathway and
activation of transcription factors BLIMP1 (also known as PR domain zinc finger protein 1
(PRDM1)) and PRDM14 (REFs 43,44). These founder cells of the germ line begin to
migrate at E8.5 and arrive at the genital ridge at E11.5. At the beginning of their
specification and migration, PGCs are thought to have the same epigenetic marks as other
epiblast cells. However, by the time they arrive at the genital ridge, many of these marks
including DNA methylation have been erased45-47 (FIG. 2b). Given that PGCs have
undergone several cell cycles in the presence of DNMT1, this demethylation event is
considered to be active. It is thought that global demethylation, including that of imprinted
genes, takes place so that new DNA methylation patterns can be re-established, although
experimental evidence supporting this remains to be shown.
Loci-specific active demethylation in somatic cells
Active DNA demethylation has also been reported in somatic cells, but only at specific
genomic loci in response to certain signals. For example, within 20 minutes of stimulation,
activated T lymphocytes undergo active demethylation at the interleukin-2 promoter-
enhancer region in the absence of DNA replication48. Locus-specific demethylation has also
been reported to occur at the promoter of brain-derived neurotrophic factor (BDNF)49, the
protein product of which is important for adult neural plasticity (FIG. 3a). In unstimulated
neurons, the BDNF promoter is methylated, allowing for the recruitment of the repressive
meC-binding protein, MeCP2. when depolarized with KCl, BDNF is upregulated,
coinciding with the release of MeCP2 and demethylation of the promoter49. Because this
event takes place in post-mitotic neurons, active demethylation is thought to be the
underlying mechanism. In addition to T cells and neurons, active DNA demethylation has
been reported to take place during nuclear hormone-regulated gene activation (FIG. 3b). For
example, the pS2 (also known as TFF1) promoter exhibits periodic methylation and
demethylation that coincides with cyclical binding of oestrogen receptor-α (Erα) and
expression of pS2 (REFs 50,51). Similarly, active DNA demethylation occurs at the
cytochrome p450, subfamily 27B, polypeptide 1 (CYP27B1) promoter in response to
parathyroid hormone (PTH)52. These studies suggest that DNA methylation may not
function solely as a long-term silencing mark, but could also function in the dynamic
regulation of genes that require rapid responses to specific stimuli.
Mechanisms of active DNA demethylation
The importance of DNA methylation in diverse biological processes coupled with the
observations of active DNA demethylation in embryonic development and somatic cells
have led to extensive efforts in identifying DNA demethylases. DNA demethylase activity
was first reported in murine erythroleukaemic nuclear extracts53. Although it was
determined that 5meC was ultimately replaced by C in a replication-independent manner,
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this activity has not been further characterized. A DNA demethylase activity was also seen
in rat myoblasts54. However, its sensitivities towards RNase and protease treatments were
conflicting55 and this activity was not pursued further.
Since then, several studies have led to the proposal of various mechanisms by which active
DNA demethylation can occur. These include: enzymatic removal of the methyl group of
5meC, base excision repair (BER) through direct excision of 5meC, deamination of 5meC to
T followed by BER of the T•G mismatch, nucleotide excision repair (NER), oxidative
demethylation and radical S-adenosylmethionine (SAM)-based demethylation.
Enzymatic removal of the methyl group of 5meC
The simplest way to achieve DNA demethylation is through enzymatic removal of the
methyl group of 5meC. This requires an enzyme with enormous catalytic power because of
the strength of the carbon-carbon bond that needs to be broken. Methyl-CpG-binding
domain protein 2 (MBD2) was the first reported protein to carry out this reaction. It did not
require any specific cofactors, and was proposed to release methanol56. This
thermodynamically unfavourable mechanism was hotly contested for several reasons. First,
previous studies had shown that MBD2 can stably bind methylated DNA57,58, making it
unclear how binding could occur if MBD2 was so efficient at removing the methyl group.
Further concerns were raised when MBD2-null mice were not only viable, but also exhibited
normal methylation patterns59. Importantly, the paternal pronucleus of MBD2-null zygotes
still exhibit normal demethylation31. These observations, coupled with the fact that no other
laboratories could reproduce the reported enzymatic activity, have raised serious doubts on
the capacity of MBD2 to serve as a DNA demethylase. Regardless of the controversy
surrounding MBD2, it is still conceivable that a bona fide DNA demethylation mechanism
exists. In fact, numerous histone demethylases that can break a carbon-nitrogen bond have
recently been discovered60,61. Although carbon-carbon bonds are inherently more difficult
to break than carbon-nitrogen bonds, enzymes that have the capacity to do so have been
reported in the thymidine salvage pathway62 and the cholesterol synthesis pathway63.
BER through direct excision of 5meC
It has been proposed for some time that DNA demethylation can be achieved through the
BEr DNA repair pathway (FIG. 4a). This type of repair involves a DNA glycosylase that
removes the target base resulting in an abasic (apurinic and apyrimidinic (AP)) site. The
DNA backbone is subsequently nicked by an AP lyase activity to generate a 5′
phosphomonoester and a 3′ sugar phosphate residue. An AP endonuclease then removes the
3′ sugar group leaving a single nucleotide gap that is ultimately filled in by DNA repair
polymerases and ligases64.
Active DNA demethylation can be accomplished by a DNA glycosylase that directly excises
5meC to initiate BER (FIG. 4a). Strong genetic and biochemical evidence supports the use
of this mechanism in plants65. In Arabidopsis thaliana, DNA demethylation is mediated by
the Demeter (Dme) family of DNA glycosylases, which consists of four members: DME,
repressor of silencing 1 (ROS1; also known as DML1), DML2 and DML3 (REF. 65). The
discovery that these DNA glycosylases suppress DNA methylation initially came from
forward-genetic screens in A. thaliana. whereas DME was discovered owing to the loss of
expression of the imprinted gene MEDEA in a loss-of-function DME mutant66, ROS1 was
recovered in a genetic screen for mutants that confer promoter hypermethylation and
transgene silencing defects67.
DME, ROS1, DML2 and DML3 possess glycosylase activity against oligonucleotides
containing 5meC67-71. In addition, all members of the Dme family possess AP lyase activity
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and are thus considered bifunctional glycosylases69-71. Besides CpG, DNA methylation in
plants can occur in the context of CpNpG (where N is A, T or C) and CpNpN. All members
of the Dme family have the capacity to recognize and remove meC bases from double-
stranded DNA (dsDNA) oligonucleotides, irrespective of their sequence context in vitro71.
However, attempts to determine the substrate specificity of these enzymes have resulted in
conflicting reports owing to the use of different substrates and reaction conditions68-71. In
vivo studies indicate that mutation of each of these genes results in hypermethylation in all
sequence contexts but at distinct genomic loci69,71-73, indicating that each of these enzymes
has a unique in vivo function.
Although it is clear that plants use BER to achieve DNA demethylation, evidence supporting
a similar mechanism in mammals has been less compelling. Despite the lack of an obvious
mammalian orthologue of the ROS1 family, the first indication that a repair mechanism
could contribute to DNA demethylation came from early studies in chicken embryo
extracts74, revealing 5meC glycosylase activity against hemi-methylated DNA75.
Subsequent purification of this activity showed that it has three components: RNA, an RNA
helicase related to the human p68 DEAD-box protein and a homologue of human T DNA
glycosylase (TDG)76-78. Thus, 5meC glycosylase activity initially detected in chicken
embryo extracts was attributed to TDG. However, its excision activity against 5meC was
30-40-fold lower compared with that against T78. Although TDG can flip C and C analogues
into its active site, it does not possess the catalytic power to break the N-glycosidic bond79.
It should be noted that the excision activity of TDG against 5meC is stimulated by the
presence of both RNA and the RNA helicase78. Similarly, both DNMT3A and DNMT3B
have been reported to interact with and stimulate the enzymatic activity of TDG80,81. Future
work should determine whether these interactions have an effect on substrate preference in
vitro and whether loss of function of TDG has an effect on DNA methylation status in vivo.
In addition to TDG, the methyl-CpG-binding protein MBD4 has glycosylase activity against
5meC, but again this activity is 30-40-fold lower than its T•G mismatch glycosylase
activity82. Not surprisingly, MBD4-null zygotes exhibit normal demethylation of the zygotic
paternal pronucleus83, and MBD4-null mice have an increased number of C to T mutations
regardless of whether the C is methylated or not84. Despite its unfavourable biochemical
properties, MBD4 was reported to carry out active DNA demethylation of the CYP27B1
promoter in response to PTH52. Interestingly, phosphorylation by protein kinase C enhanced
MBD4 glycosylase activity against 5meC52, which may partially explain earlier enzymatic
studies showing MBD4’s preference for C over 5meC85.
Deamination of 5meC to T followed by BER
DNA demethylation can also be achieved by deamination of 5meC to produce T, followed
by BER to replace the mismatched T with unmethylated C (FIG. 4b). Both cytidine
deaminases and DNMTs have been proposed to carry out the first step of this mechanism.
on deamination of 5meC, T glycosylases such as TDG and MBD4 (see above) may function
by repairing the mismatch.
Cytidine deaminases are important players in diverse biological processes such as the
generation of antibody diversity, RNA editing and retroviral defence86. These processes
require the production of mutations in DNA and RNA, which is achieved, in part, through
the deamination of cytidine to uridine by the activation-induced deaminase (AID) and
apolipoprotein B mRNA editing enzyme, catalytic polypeptide (APOBEC) family of
proteins. APOBEC1, the founding member of this family, is involved in editing
apolipoprotein B pre-mRNA87,88. The related deaminase AID was discovered to be essential
for somatic hypermutation and class switch recombination of immunoglobulin genes in B
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cells89,90. Consistent with its role in the diversification of antibodies, AID-deficient mice are
viable and fertile and significant phenotypic abnormalities are seen only in B cells89,90.
Despite the lack of developmental defects in AID-knockout mice, both AID and APOBEC1
have been shown in vitro and in an E. coli assay to have the capacity to deaminate 5meC to
T in the context of single-stranded DNA91. AID and APOBEC1 are also expressed in mouse
oocytes, ES cells and PGCs, which may be a consequence of their genomic location in a
cluster of pluripotency genes that include nanog and stella (also known as DPPA3 and
PGC7)91. Nevertheless, expression of AID in PGCs and the early embryo points to a
possible role in global DNA demethylation. Indeed, a recent large-scale bisulphite
sequencing study indicates that DNA methylation levels of male and female PGCs derived
from AID-null embryos increased about 4% (from 18% to 22%) and 13% (from 7% to
20%), respectively, when compared to their wildtype counterpart92, suggesting that AID
may contribute to PGC demethylation. However, because the DNA methylation levels in
AID-null PGCs (~20%) are still relatively low compared with ES or somatic cells (70-80%),
considerable demethylation still occurs in the absence of AID, indicating that other factors
responsible for PGC demethylation remain to be identified.
Nevertheless, studies in zebrafish embryos have suggested that Aid, Mbd4 and the DNA
repair protein Gadd45a (growth arrest and DNA-damage-inducible 45α) can cooperate in
demethylating a methylated DNA duplex93. In this study, when a methylated linear dsDNA
of ~740 bp was injected into a zebrafish embryo, demethylation of the injected DNA was
seen when Aid and Mbd4 were co-expressed. The authors postulated that Aid de aminated
5meC, allowing Mbd4 to excise the T•G mismatch. Indeed, the T•G mismatch was detected
using a PCR strategy, but only when Aid was expressed with a catalytic mutant of Mbd4
because the wild-type version excised the mismatch too quickly for it to be detected.
Furthermore, when Aid and Mbd4 were titrated to levels that did not cause demethylation,
the inclusion of Gadd45a elicited demethylation, indicating that these three proteins act
cooperatively93.
Although the above studies have provided some evidence that AID may contribute to
mammalian DNA demethylation, decisive biochemical and genetic evidence supporting a
major role in this process is still lacking. Biochemically, AID can act on 5meC in the
context of single-stranded DNA but not dsDNA91. Genetically, AID-knockout mice exhibit
the expected B cell and immunological defects89,90, but no gross developmental or
reproductive defects. Similarly, APOBEC1-knockout mice are also viable and fertile94,95.
Although genetic redundancy may be a possible cause of the lack of expected developmental
and reproductive phenotypes, such explanation needs to be confirmed by generating
combinational knockouts. Furthermore, because DNA methylation occurs symmetrically,
deamination of both strands would give rise to a TG•GT double mismatch. There is no
evidence indicating that either TDG or MBD4 can use a double mismatch as a substrate.
Furthermore, processing of a double mismatch by the AP endonuclease would generate a
DNA double-strand break. This would put tremendous pressure on the repair machinery if
such a mechanism were used for global demethylation. However, for locus-specific DNA
demethylation, such a mechanism would not present a big problem.
In addition to AID and APOBEC, DNMTs have recently been implicated in 5meC
deamination, even though they are commonly known for their ability to catalyse DNA
methylation. Evidence indicating their involvement in the deamination process initially
came from studies in bacteria where the methyltransferases M. HpaII96-98 and M.
EcorII99,100 were shown to possess deaminase activities. Consistent with bacterial studies,
the mammalian counterparts, DNMT3A and DNMT3B, have also been shown to possess
deaminase activity in vitro51. As discussed above, the promoters of oestrogen-responsive
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genes undergo cyclical rounds of methylation and demethylation. Thus, the participation of
DNMT3A and DNMT3B in both methylation and demethylation would facilitate rapid
transcriptional cycling (FIG. 3b). Interestingly, ERα associates with and stimulates the
activity of TDG101,102, allowing for the repair of the T•G mismatch. DNMT3A and
DNMT3B also associate with TDG and this interaction stimulates glycosylase activity80,81.
Indeed, DNA demethylation was found to coincide with the recruitment of TDG and other
BER enzymes51.
However, it is surprising that DNMTs possess two opposing enzymatic activities. Although
the methyltransferase activity of DNMT3A is inhibited by TDG81, the 5meC deamination
reaction can only occur under conditions where SAM concentrations are very low or
nonexistent51. In order for DNMT3A to carry out efficient methylation and demethylation
during transcriptional cycling, levels of SAM must fluctuate rapidly. Given that SAM is
crucial for many essential biochemical and biological processes, it is difficult to imagine
how this could be achieved without serious biological consequences.
Nucleotide excision repair
Another DNA repair pathway, NER, has also been proposed to carry out DNA
demethylation. This type of repair is generally used to repair DNA containing bulky lesions,
which form after exposure to chemicals or radiation. After damaged DNA is recognized,
dual incisions flanking the lesion are made and a 24-32 nucleotide oligomer is released. The
resulting gap is then filled in by repair polymerases and sealed by a ligase64.
In an assay aimed at identifying proteins required for activation of a reporter that is silenced
by DNA methylation, Niehrs and colleagues uncovered a novel function for GADD45A103,
which is encoded by a p53- and breast cancer type 1 susceptibility protein (BRCA1)-
inducible gene and participates in diverse biological processes, including DNA damage
response, cell cycle progression, apoptosis and NER104. Overexpression of GADD45A in
mammalian cell lines leads to loci-specific and global demethylation, whereas knockdown
results in DNA hypermethylation103. Because GADD45A had previously been implicated in
NER105,106, Barretto et al. explored the role of NER in DNA demethylation and found that
loss of DNA methylation is accompanied by DNA synthesis and requires the NER
endonuclease xeroderma pigmentosum group G-complementing protein (XPG), which
interacts with GADD45A103. The recruitment of GADD45A and other components of the
NEr repair machinery to ribosomal RNA (rRNA) genes is facilitated by TBP-associated
factor 12 (TAF12) and leads to DNA demethylation and rRNA gene activation107. However,
it is not clear how the demethylation process is initiated and whether GADD45A is directly
involved. More importantly, two independent studies have raised doubt on the role of
GADD45A in the active DNA demethylation process. In the first study, the Pfeifer group
carried out a series of experiments that were similar to those carried out by the Niehrs group,
but obtained no evidence indicating that GADD45A had any effect on DNA methylation108.
In the second study, analysis of the GADD45A-null mice indicated that loss of GADD45A
function had neither loci-specific nor global effects on DNA methylation levels109.
GADD45B, another member of the GADD45 family, has also been implicated in active
demethylation of genes that are crucial for adult neurogenesis110. Loss of GADD45B results
in defects in neural progenitor proliferation and dendritic growth. This was attributed to
promoter hypermethylation and the repression of BDNF and fibroblast growth factor 1
(FGF1), two genes crucial for neurogenesis110. However, GADD45B is not involved in
zygotic DNA demethylation as GADD45B-null zygotes undergo normal paternal genome
demethylation111. Because GADD45B has not been biochemically characterized, it is
unknown whether it is directly involved in the active demethylation of neurogenesis genes.
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Another possible mechanism by which DNA demethylation can be carried out is through
oxidative demethylation. The E. coli enzyme AlkB is a member of the 2-oxoglutarate
(2OG)-dependent dioxygenases and is involved in the bacterial response to alkylation
damage to DNA. using oxygen, iron and 2OG as cofactors, AlkB is able to carry out
oxidative demethylation of 1-methyladenine and 3meC by releasing the methyl group as
formaldehyde112,113. The same mechanism is used by the JmjC family of enzymes to
demethylate histon e substrates60,114.
Although breakage of a carbon-carbon bond is energetically difficult, enzymes that catalyse
such reactions do exist. As shown in FIG. 5a, thymine 7-hydroxylase can catalyse the
conversion of T to iso-orotate through three consecutive oxidation reactions using oxygen,
iron and 2OG as cofactors115. Iso-orotate can be further converted to C through a
decarboxylation reaction. Although thymine 7-hydroxylase and iso-orotate decarboxylase
have been isolated from fungi, such as Rhodotorula glutinis, Neurospora crassa and
Aspergillus nidulans62, no homologue of thymine 7-hydroxylase has been found in
mammals. Interestingly, the trypanosome base J-binding proteins, JBP1 and JBP2, have
properties similar to that of thymine 7-hydroxylase 116,117, prompting the Rao group to
search for mammalian homologues with similarity to the dioxygenase domains of the JBP
proteins. This effort led to the identification of the ten-eleven translocation (TET) family of
proteins118. we have also independently characterized the mouse TET family119.
TET1, the founding member of the TET family, was initially discovered in acute myeloid
leukaemia (AMl) as a fusion partner of the histone H3 Lys4 methyltransferase MLL120,121.
Subsequent studies in vitro and in cultured cells showed that human TET1 is capable of
hydrolysing 5meC to produce 5-hydroxymethylcytosine (5hmC) in DNA118. Similarly, all
three members of the mouse TET family possess this enzymatic activity119. Consistent with
the presence of a dioxygenase domain in the proteins and the predicted reaction mechanism,
the putative iron-binding sites are required for their enzymatic activities118,119. Furthermore,
TET1 is capable of acting on both fully methylated and hemi-methylated DNA118.
Although 5hmC has previously been reported to exist in animal DNA122, this modified base
is not found in some cell types and tissues118,123, thus raising the question of whether 5hmC
is present in mammalian DNA at physiologically relevant levels. This issue was directly
addressed in two cell types. In Purkinje neurons, 5hmC is ~40% as abundant as 5meC124,
whereas the frequency of 5hmC in ES cells was estimated to be approximately 1 in every
3,000 nucleotides118. Thus, it is evident that 5hmC constitutes a large fraction of
mammalian DNA in some cell types.
The consequences of 5hmC in genomic DNA are currently unclear. Because 5hmC seems to
be stable, it may function like other modifications by altering local chromatin structure or
contributing to the recruitment or exclusion of other factors that influence transcription. For
example, the transcriptional repressors MeCP2, MBD1, MBD2 and MBD4 bind to
methylated DNA, but do not recognize 5hmC125,126. It is also possible that the TET proteins
may facilitate passive demethylation in dividing cells such as ES cells as 5hmC is not
recognized by DNMT1 (REF. 127); thus, newly replicated DNA would not maintain
patterns of methylation. Alternatively, 5hmC may be an intermediate in an active
demethylation pathway that ultimately leads to the replacement of 5meC with C (FIG. 5b).
This could be achieved by several ways that include: BER by a 5hmC-specific DNA
glycosylase (as such activity has been previously reported to exist in calf thymus
extracts128), deamination of 5hmC to generate 5hmu followed by BER initiated by a 5hmu-
specific glycosylase such as single-strand-selective monofunctional u DNA glycosylase 1
(SMUG1)129, conversion of 5hmC to C through loss of formaldehyde on ultraviolet light
Wu and Zhang Page 9













exposure130 or high pH131 (or possibly carried out by DNMTs)132, and two consecutive
oxidation steps followed by decarboxylation similar to that used by the thymidine salvage
pathway (FIG. 5a). It is not clear why TET proteins cannot catalyse consecutive reactions
such as that of thymine 7-hydroxylase. Because all in vitro assays carried out so far used
recombinant TET proteins alone, it is possible that association of TET proteins with their in
vivo partners is necessary to confer such a capability. In this case, a decarboxylase may
eventually remove the carboxyl group to complete the demethylation process.
Consistent with the relative enrichment of 5hmC in ES cells, recent studies have shed light
on the role of TET1 in ES cell biology. During ES cell differentiation, TET1 mRNA levels
decline, coinciding with a decrease in 5hmC levels118, which suggests that TET1 may be
important for ES cell identity. Indeed, knockdown of TET1, but not TET2 or TET3, in
mouse ES cells results in impairment of ES cell self-renewal and maintenance119. Analysis
of the differentiated TET1-knockdown ES cells revealed a bias towards the trophoectoderm
and primitive endoderm lineages. Furthermore, knockdown of TET1 at two-cell stage
embryos followed by cell lineage tracing revealed that the knockdown cells are biased
towards the trophoectoderm119, indicating that TET1 is required for inner cell mass cell
specification. Consistent with its role in ES cell self-renewal and maintenance, knockout of
TET1 resulted in embryonic lethality (K. Hong and Y.Z., unpublished observations), making
the evaluation of the role of TET1 on global demethylation of the paterna l genome difficult.
With regard to the mechanism underlying the role of TET1 in ES cells, TET1 maintains
nanog expression in ES cells by directly binding to the nanog promoter and protecting it
from becoming hypermethylated, as knockdown of TET1 in ES cells resulted in
downregulation of nanog expression concomitant with increased nanog promoter
methylation119. Nanog seems to be one of the main TET1 targets as the phenotypes
associated with TET1 knockdown can largely be rescued by ectopic expression of nanog119.
Although TET2 is also expressed in ES cells, it seems that TET2 does not play a significant
part in ES cell biology as knockdown of TET2 does not confer any obvious phenotype 119.
However, a flurry of recent studies have uncovered that dysfunction of human TET2 may be
a key event in leukaemogenesis as human TET2 is mutated in a range of human myeloid
malignancies, including myelodysplastic syndromes (MDSs), myeloproliferative disorders
(MPDs) and acute myeloid leukaemias (AMls)133-140. Currently, TET2 is the most
frequently mutated gene that has been identified in patients with MDS and these mutations
have been suggested to occur early during the pathogenesis of the disease137. Consistent
with a role for TET2 in regulating DNA demethylation, aberrant DNA methylation is
frequently found in patients with MDS141. Indeed, mutations of TET2 that mimic mutations
identified in patients with MDS abolished the enzymatic activity of TET2 (A. C. D’Alessio
and Y.Z., unpublished observations). Furthermore, the DNA methyltransferase inhibitor 5-
azacytidine (5-azaC) has been shown to be an effective treatment for patients with high-risk
MDS and secondary AML142,143, indicating that aberrant DNA methylation plays a crucial
part in MDS development and progression. The participation of TET2 in DNA
demethylation may provide a molecular basis for the effectiveness of using
methyltransferase inhibitors in the treatment of patients with MDS, thus setting the stage for
understanding the molecular mechanism underlying the pathogenesis of leukaemias.
Radical SAM mechanism
Although many proteins have been proposed to carry out active DNA demethylation, none
of the proteins discussed above have been shown to have a role in paternal genome
demethylation in zygotes. To identify proteins involved in paternal genome demethylation,
our laboratory used a candidate gene knockdown approach coupled with live-cell imaging.
To facilitate a screen of candidate proteins, we developed a probe that consists of the Cys-X-
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X-Cys domain of MLL fused to enhanced green fluorescent protein (EGFP). Because the
Cys-X-X-Cys domain has high affinity for unmethylated CpG144, injection of mRNA
encoding the probe into zygotes results in the accumulation of the probe at the demethylated
paternal pronucleus111, allowing live-cell imaging of the paternal genome demethylation
process. Using this imaging system, we screened several candidate proteins by injecting
small interfering RNAs (siRNAs) against each of the candidates into eggs before carrying
out intracytoplasmic sperm injection (ICSI), and monitored the effect of the siRNA on the
accumulation of the probe at the paternal pronucleus. This screen uncovered a role for
elongator complex protein 3 (ELP3) in paternal genome demethylation. ELP3 knockdown
prevented the accumulation of the probe in the paternal pronucleus at pronuclear stages 4
and 5 (REF. 111). In addition, immunostaining and bisulphite sequencing of selected
retrotransposon elements further support a role for ELP3 in paternal genome
demethylation111.
ELP3 is a member of the core elongator complex (ELP1-ELP3), which combines with
another subcomplex (ELP4-ELP6) to form the holo-elongator complex145,146. Because
knockdown of the ELP1 and ELP4 components also impaired paternal genome
demethylation, it is likely that the entire elongator complex may be involved in the
demethylation process111. Interestingly, the Fe-S radical SAM domain of ELP3, but not the
histone acetyltransferase (HAT) domain, is required for paternal genome demethylation111.
Although this may provide a clue regarding the enzymatic mechanism of ELP3, recent
studies in yeast suggest that the Cys-rich domain of Elp3 is required for the integrity of the
elongator complex147,148, raising the possibility that the Fe-S radical SAM motif may have a
structural rather than an enzymatic role. Thus, direct biochemical evidence of the enzymatic
activity of the elongator complex and genetic evidence using ELP3-null oocytes remain to
be shown.
Interestingly, a recent study confirmed the presence of an Fe-S cluster in the bacteria
Methanocaldococcus jannaschii Elp3 protein149. The assumption that mammalian ELP3 is a
radical SAM protein has led to a potential mechanism for ELP3-catalysed DNA
demethylation as outlined in FIG. 6 (S. J. Booker, personal communication). like every
radical SAM enzyme, the reaction is initiated by the generation of a powerful oxidizing
agent, the 5′-deoxyadenosyl (5′-dA) radical, from SAM. The 5′-dA radical could extract a
hydrogen atom from the 5-methyl group to generate a 5meC radical. In the next step, an
electron is returned back to the Fe-S cluster to generate a third intermediate, which can be
converted to the relatively stable 5hmC by the addition of a water molecule. In order to
break the carbon-carbon bond, the next step requires the generation of an intermediate, the
resulting carbanion of which would be stabilized. This can probably be achieved by a
thymidylate synthase or methyltransferase type of mechanism, whereby a Cys residue
carries out a nucleophilic attack at carbon 6, leading to the release of formaldehyde. In the
absence of an external nucleophile, an alternative pathway leading to the release of
formaldehyde can also take place. Finally, an elimination at the formaldehyde release step
results in the final product of C.
Although future studies are required to validate or refute this proposed mechanism, we note
that this work is not trivial for three reasons. First, the identities of mammalian ELP5 and
ELP6 still need to be determined as an apparent orthologue of yeast Elp5 and Elp6 cannot be
identified by sequence homology searches. Second, the radical SAM reaction occurs under
anaerobic conditions and reconstitution of the elongator complex under anaerobic conditions
is challenging. Finally, given that zygotic DNA demethylation occurs only on the paternal
genome, some unique features of the paternal genome may be required in order for it to
serve as a substrate. Despite these challenges, identification of the elongator complex as an
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important factor for paternal genome demethylation in zygotes allows for further studies
towards understanding the molecular mechanisms of active DNA demethylation.
Concluding remarks
Observations of active DNA demethylation during embryonic development and in somatic
cells have opened the door for many questions to be answered. In particular, how DNA
demethylation is achieved in mammalian cells remains debatable as no single enzyme or
mechanism has gained decisive biochemical and genetic support (see Supplementary
information S1 (table)). It is possible that multiple mechanisms exist to carry out DNA
demethylation and that the use of each one is dictated by the specific biological context.
Although repair-based mechanisms, particularly deamination of 5meC followed by BER,
have offered an attractive mechanism for active DNA demethylation, genetic evidence is
still lacking. Furthermore, the involvement of a repair-based mechanism in global DNA
demethylation would put tremendous pressure on the repair machinery when considering
that paternal pronucleus demethylation is completed within 4 hours17,18.
Although AID seems to contribute to active demethylation in PGCs, it is only responsible
for a small part of it as considerable demethylation still takes place in the AID-null PGCs92.
Nevertheless, this mechanism does provide a reasonable explanation for loci-specific
demethylation in response to gene-activation signals. Although AID deficiency has some
effect on PGC demethylation, there is no evidence that it affects paternal DNA
demethylation in zygotes. Similarly, MBD4-null zygotes still experience paternal genome
demethylation83. It seems that although repair-based mechanisms may be responsible for
loci-specific DNA demethylation and partial demethylation in PGCs, their role in zygotic
paternal genome demethylation is less likely. To date, the only factor shown to have a role
in zygotic paternal genome demethylation is the elongator complex, although it is unclear
whether its role is direct or indirect111. Future work should focus on gaining additional
genetic evidence using elongator-null zygotes and elucidating its enzymatic activity. The
recent demonstration that the TET family proteins are capable of catalysing the conversion
of 5meC to 5hmC has raised the possibility that these proteins may have a role in active
DNA demethylation118,119. we anticipate that work evaluating their role in demethylation of
the zygotic paternal genome and PGCs is forthcoming. Furthermore, analysis of the fate and
function of 5hmC will also attract a lot of attention.
In addition to determining the mechanism of active demethylation, one open question that
remains is to what extent the paternal genome and PGCs are demethylated. Although this
event is considered to be global, as determined by 5meC immunostaining, it is evident that
some regions of the paternal genome are protected from this wave of demethylation. The
advent of high-throughput analyses including chromatin immunoprecipitation-on-chip
(ChIP-chip), ChIP sequencing (ChIP-Seq) and bisulphite sequencing (BS-Seq; bisulphite
treatment followed by high-throughput sequencing) has allowed for genome-wide profiling
of epigenetic marks such as DNA methylation92,150-153. using single-molecule, realtime
sequencing, a recent study showed the feasibility of direct detection of modified nucleotides
in DNA, including N6-meA, 5mC and 5hmC154. Future studies using these tools will
undoubtedly determine precisely which genomic regions are demethylated and which
regions are protected. However, improvements in the sensitivity of these technologies will
be necessary for such experiments, given that paternal genomic DNA would need to be
obtained from individual zygotes.
As well as being fundamental to our knowledge in epigenetics, a better understanding of
how DNA demethylation occurs will allow for the development of techniques and
approaches that will improve somatic cell reprogramming (BOX 2) and cancer treatment.
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Tumour suppressor gene silencing by promoter DNA methylation is thought to play an
important part in cancer development155. Consistently, inhibitors of DNMTs have been used
in the treatment of certain cancers156. Owing to the reversible nature of epigenetic
modifications, developing drugs that target epigenetic factors is becoming one of the top
priorities for many biotechnology and pharmaceutical companies157. It is anticipated that
targeted demethylation of tumour suppressor genes may reactivate the silenced tumour
suppressor genes, which can lead to cellular differentiation or halt uncontrolled cell
proliferation.
The mechanism underlying the regulation of DNA methylation is a question that has elicited
much attention and controversy over the past decade. Although recent studies have proposed
numerous ideas as to how active DNA demethylation is carried out, many aspects are still
contentious and a consensus has yet to be achieved. with the development of new
technology and the studies described above, our continued and collective efforts in this field
will hopefully provide clearer answers in the coming decade.
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Refer to Web version on PubMed Central for supplementary material.
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Glossary
Imprinted gene A gene that is expressed in a parent-of-origin-specific manner.
Inactive X
chromosome
The copy of X chromosome that is silenced in female
chromosomes in order to equalize the expression of genes
located in the X chromosome in males and females.
DNA
methyltransferase




Duplex DNA in which only one of the two strands is
methylated.
Zona pellucida The glycoprotein coat that surrounds the oocytes and the early
embryos of mammals.
Polar body The structure that is extruded from the oocyte during meiosis
and contains one haploid set of chromosomes
Parthenogenesis The production of a diploid offspring from two sets of haploid
maternal gametes and no paternal contribution
Gynogenesis Parthenogenesis in which the embryo contains only maternal
chromosomes owing to the failure of the sperm to fuse with the
egg nucleus
Digynic triploid An embryo that contains two maternal genomes and one paternal
genome.
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Bisulphite sequencing A technique in which the treatment of DNA with bisulphite,
which converts C to U but does not modify meC, is used to
determine the DNA methylation pattern.
Blastocyst An embryonic stage that is characterized by the formation of the
first definitive lineages.
Primordial germ cell One of a population of embryonic cells from which germ cells
are formed.
RNA editing The post-transcriptional modification of RNA primary sequence
by the insertion and/or deletion of specific bases, or the chemical
modification of adenosine to inosine or cytidine to uridine.
Somatic
hypermutation
The mutation of the immunoglobulin variable region in mature
B cells during an immune response. It results in affinity
maturation of the antibody response. Like class switch




A mechanism that changes the class or isotype of antibody
produced by an activated B cell. This does not change the
affinity towards an antigen, but instead allows for interaction
with different effector molecules.
JmjC (Jumonji C). An evolutionarily conserved motif. Proteins




A protein that binds to base J (β-D-glucosylhydroxymethyl-U),
a modified T produced by hydroxylation and glucosylation of
the methyl group of T.
Elongator complex A protein complex originally identified in budding yeast to be
associated with the elongating and hyperphosphorylated RNA
polymerase II. It has also been implicated in tRNA modification,
exocytosis and neuronal maturation.
SAM domain A protein domain containing an Fe-s cluster that uses s-
adenosylmethionine (sAM) to catalyse various radical reactions.
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Protection of the maternal genome from demethylation
Whereas the paternal genome undergoes extensive demethylation, the maternal genome
remains methylated even though it is exposed to the same cytoplasmic factors. This may
be due to a mechanism that protects the maternal genome from this wave of
demethylation or to a putative DNA demethylase that is specifically recruited to the
paternal genome.
Sperm DNA is packaged with protamines, which are exchanged for canonical and
noncanonical histones on fertilization. Interestingly, deposition of the histone variant
H3.3 occurs asymmetrically, with a strong preference for the paternal pronucleus158,159.
This raises the possibility that asymmetric H3.3 deposition may trigger the paternal
genome-specific demethylation process. Asymmetric patterns of histone modifications
have also been seen in the maternal and paternal pronuclei and may also contribute to the
asymmetric demethylation process. For example, methylation, dimethylation and
trimethylation at H3 Lys27 (H3K27me1, H3K27me2 and H3K27me3, respectively) and
at Lys9 (H3K9me2 and H3K9me3) are clearly seen in the maternal pronucleus of
zygotes, but are virtually undetectable in the paternal pronucleus159-164. Thus, the
maternal genome may use a protective mechanism against demethylation by carrying
specific histone variants or modifications.
Alternatively, a recent study has suggested that non-histone factors present in the oocyte
might protect the maternal genome from demethylation165. Zygotes lacking stella (also
known as DPPA3 and PGC7), a maternal effect gene required for early development166,
exhibited demethylation of both pronuclei. Although stella can directly bind DNA in
vitro, it seems to lack specificity for methylated DNA165. Therefore, how stella protects
the maternal genome from demethylation remains to be determined.
Wu and Zhang Page 23














Implications of active DNA demethylation in reprogramming
Induced pluripotent stem (iPS) cells can be generated by introducing four transcription
factors — octamer-binding protein 3 (OCT3; also known as OCT4 and POU5F1), SRY
box-containing factor 2 (SOX2), krüppel-like factor 4 (KLF4) and MYC — into somatic
cells167,168. Successful reprogramming requires the activation of endogenous OCT4 and
nanog genes, which are known to be silenced by DNA methylation in somatic
cells169-172. Demethylation of the OCT4 and nanog promoters is thus an integral event in
iPS cell generation173. In fact, inefficient DNA demethylation is thought to be one of the
causes of the low efficiency in iPS cell generation because the use of the DNA
methylation inhibitor 5-azacytidine can increase the efficiency of iPS cell generation by
converting partially reprogrammed cells to fully reprogrammed iPS cells173.
Transcription factor-based iPS cell generation is a slow process compared to somatic cell
nuclear transfer (SCNT) and cell fusion174,175. One possible explanation for this
difference may be the mechanisms used to reactivate endogenous OCT4 and nanog.
Epigenetic reprogramming of somatic cells to pluripotent iPS cells may necessitate
several cell divisions176 owing to the absence of the DNA demethylase or demethylases
required for demethylation of the OCT4 and nanog promoters. By contrast, reactivation
of OCT4 and nanog can occur quickly during SCNT and cell fusion because the DNA
demethylase or demethylases may already be present in eggs and embryonic stem (ES)
cells. Consistent with this notion, reprogramming by cell fusion requires activation-
induced deaminase (AID)-dependent demethylation and reactivation of OCT4 and
nanog177. Surprisingly, although AID was present at the OCT4 and nanog promoters in
fibroblasts, these promoters are methylated, suggesting that other factors or regulatory
events are required for demethylation. Given that genetic evidence does not support an
important role for AID in ES cells (see main text), it is unclear whether AID directly
participates in promoter demethylation of these genes during somatic cell
reprogramming. Regardless, it is evident that activation of pluripotent genes through
DNA demethylation is an important step during the somatic cell reprogramming process.
Identification and characterization of the enzymes involved should improve protocols of
somatic cell reprogramming.
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Figure 1. Mechanisms of DNa methylation and demethylation
During early development, methylation patterns are initially established by the de novo
DNA methyltransferases DNMT3A and DNMT3B. When DNA replication and cell division
occur, these methyl marks are maintained in daughter cells by the maintenance
methyltransferase, DNMT1, which has a preference for hemi-methylated DNA. If DNMT1
is inhibited or absent when the cell divides, the newly synthesized strand of DNA will not be
methylated and successive rounds of cell division will result in passive demethylation. By
contrast, active demethylation can occur through the enzymatic replacement of 5-
methylcytosine (5meC) with C.
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Figure 2. Dynamics of DNa methylation during development
a | Active demethylation in the zygotic paternal genome. Shortly after a sperm fertilizes an
egg, the paternal genome rapidly undergoes genome-wide active DNA demethylation and
remains demethylated following multiple rounds of cell division. During this time, the
maternal genome experiences gradual, passive demethylation. De novo methylation patterns
are established by the DNA methyltransferases DNMT3A and DNMT3B during the
development of the blastocyst. b | Active demethylation in primordial germ cells (PGCs).
After implantation of the blastocyst at embryonic day 7.5 (E7.5), the extraembryonic
ectoderm (ExE) and visceral endoderm (VE) produce signals that specify a subset of epiblast
cells (Epi) to become PGCs. This process requires two key transcription factors, BLIMP1
(also known as PR domain zinc finger protein 1 (PRDM1)) and PDRM14, which are
expressed during this stage of development. Following specification, PGC founder cells
divide in the presence of the DNA methyltransferase DNMT1 and migrate towards the
genital ridge. During this migration and on arrival at the genital ridge, 5-methylcytosine
(5meC) is erased through an active mechanism. ICM, inner cell mass; TE, trophectoderm.
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Figure 3. Locus-specific active DNa demethylation in somatic cells
a | Active demethylation at the brain-derived neurotrophic factor (BDNF) promoter. In
neurons, BDNF is maintained in a repressed state through DNA methylation and binding of
the repressive methylcytosine (meC)-binding protein MeCP2. On depolarization with KCl,
DNA methylation and MeCP2 binding are lost, concomitant with increased BDNF
expression. This demethylation event is considered to be active because it occurs in post-
mitotic neurons. b | Active demethylation at nuclear receptor target promoters. The promoter
of the oestrogen receptor (ER) target gene pS2 (also known as TFF1) undergoes cyclical
rounds of methylation and demethylation that correspond to the repression and expression of
the gene, respectively. Transcriptional activation of pS2 occurs in the presence of oestrogens
(E2) and coincides with demethylation of the promoter. This is achieved by deamination of
5meC by DNA methyltransferase 3 (DNMT3) followed by base excision repair (BER) of the
T•G mismatch by T DNA glycosylase (TDG). To revert to repression, DNMT3 re-
methylates the promoter. Although DNMT3 is involved in both methylation and
demethylation, it is important to note that DNMT3 can only carry out the deamination step
in the absence or at low concentrations of the methyl donor S-adenosylmethionine (SAM).
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Figure 4. Base excision repair-based mechanisms for DNa demethylation
a | Base excision repair (BER) through direct excision of 5-methylcytosine (5meC).
Initiation of the BER pathway can be carried out by a glycosylase that directly excises 5meC
to generate an abasic (apurinic and apyrimidinic (AP)) site. The DNA backbone is nicked by
an AP lyase (or by the glycosylase itself if it is bifunctional). The 3′ sugar group is then
cleaved by an AP endonuclease and the resulting single nucleotide gap is filled in with an
unmethylated C by an unknown polymerase and ligase. It has been well established in plants
that the demeter (Dme; also known as repressor of silencing 1 (ROS1)) family of enzymes
can carry out the 5meC glycosylase reaction, but to date no mammalian enzymes have been
reported to be capable of carrying out this step efficiently. b | Deamination of 5meC
followed by BER. In contrast to direct excision of 5meC, deamination of 5meC produces T,
which can be repaired by BER by a T•G mismatch glycosylase such as T DNA glycosylase
(TDG) or methyl-CpG-binding domain protein 4 (MBD4) to regenerate an unmethylated C.
DNMT, DNA methyltransferase.
Wu and Zhang Page 28













Figure 5. Oxidative demethylation by TET proteins
a | Part of the thymidine salvage pathway. Direct removal of the methyl group of 5-
methylcytosine (5meC) involves breaking a carbon-carbon bond, which requires an enzyme
with great catalytic power. Such an enzyme exists in the thymidine salvage pathway.
Starting with T, thymine-7-hydroxylase (THase) carries out three consecutive hydroxylation
reactions to produce iso-orotate, which is processed by a decarboxylase to produce U. A
similar mechanism may be used in active DNA demethylation, particularly by the ten-eleven
translocation (TET) family of proteins. b | The fate of 5-hydroxymethylcytosine (5hmC).
The TET family of proteins catalyses the conversion of 5meC to 5hmC, which may be an
intermediate that can be further processed by one of the following mechanisms. BER may be
initiated by a 5hmC glycosylase (1); 5hmC may undergo deamination to produce 5hmU (2),
which is repaired by BER through a 5hmU glycosylase such as SMUG1 (single-strand-
selective monofunctional U DNA glycosylase 1); 5hmC may directly be converted to C by
DNA methyltransferases (DNMTs), ultraviolet (UV) exposure or high pH (3); or
consecutive hydroxylation reactions followed by a decarboxylation reaction similar to the
thymidine salvage pathway may be used to ultimately replace 5hmC with C (4).
Alternatively, 5hmC itself may be a functional modification. α-KG, α-ketoglutarate.
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Figure 6. Proposed mechanism for elP3-mediated DNa demethylation
Mammalian elongator complex protein 3 (ELP3) contains an Fe-S radical S-
adenosylmethionine (SAM) domain that is important for active DNA demethylation of the
zygotic paternal genome. If ELP3 is indeed a functional radical SAM protein, it may directly
carry out DNA demethylation through the following mechanism. First, ELP3 uses SAM to
generate a 5′-deoxyadenosyl radical, which could extract a hydrogen atom from the 5-
methyl group of 5-methylcytosine (5meC; 1) to form a 5meC radical (2). After an electron is
donated back to the Fe -S to create the third intermediate (3), a water molecule would
promote the formation of 5-hydroxymethylcytosine (5hmC) (4). A nucleophilic attack at
carbon 6 can result in the carbon-carbon bond breaking to release formaldehyde (5-7). In the
absence of an external nucleophile, an alternative pathway (4′-6′) that leads to the release of
formaldehyde can also take place. Finally, an elimination step would produce an end product
of C (8).
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